Protocol Number: 94-C-0096

Title:

Adjuvant Vaccine Therapy with Tumor Specific Mutated Ras Peptides in Patients with Colon or Pancreatic Cancers

Number:

94-C-0096

Summary:

This is a dosage escalation study to estimate the optimum immunization dose of ras peptide mixed with the immunologic adjuvant Detox. Groups of 3 to 6 patients receive the ras peptide/Detox vaccine monthly for 3 months. Patients with stable or responding disease or with a specific immunologic response may receive 3 additional monthly vaccinations.

Sponsoring Institute:

National Cancer Institute (NCI)

Recruitment Detail

Type: Follow-up Of Previously Enrolled Subjects Only

Gender: Male & Female

Referral Letter Required: No

Population Exclusion(s): None

Eligibility Criteria: This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.

Special Instructions:

Many protocols are potentially hazardous, are intended only for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this protocol should be consulted before using this protocol. Dose and schedule modifications are required for patients who develop gastrointestinal, hematologic, neurologic, and biochemical (renal, hepatic, etc.) and/or other abnormalities after the administration of therapy. Additionally, Federal regulations for the protection of human subjects require approval of clinical trials by your local Institutional Review Board.

Disease Category:

PROTICD

Keywords:

Colon

Lung

T Lymphocytes

Subcutaneous

Adjuvant

Recruitment Keywords:

None

Conditions:

Neoplasm

Investigational Drug(s):

Detox

RAS Val

RAS Cys

RAS Asp

Investigational Device(s):

None

Contacts:

This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.

Citations:

P53: a frequent target for genetic abnormalities in lung cancer

Ras gene mutation in non small cell lung cancer are associated with shortened survival irrespective of treatment intent

P53 mutation in non small cell lung cancer cell line and their correlation with the presence of ras mutations and clinical features

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department of Networks and Applications, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

Warren Grant Magnuson Clinical Center (CC)
National Institutes of Health (NIH)
Bethesda, Maryland 20892. Last update: 10/19/2004